BioCentury
ARTICLE | Company News

Advanomics, Sunshine Biopharma, Laboratoires Garmen Inc. deal

September 2, 2013 7:00 AM UTC

Sunshine said its Advanomics parent company will acquire Garmen for an undisclosed amount. Garmen will manufacture 1 kg of Adva-27a, the lead compound of Advanomics and Sunshine, which will be used to complete the remaining studies required to submit an IND to FDA and conduct a Phase I trial of Adva-27a to treat breast cancer. Sunshine has an exclusive, U.S. license to Adva-27a from Advanomics, which holds a 55% stake in Sunshine. ...